No quarterly revenue total was found in ANAVEX LIFE SCIENCES CORP.'s SEC filings.
Anavex Life Sciences Corp. (AVXL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$7.82M
+159.1% vs year-ago quarter
Operating cash flow
$-9.10M
+27.0% vs year-ago quarter
Free cash flow
—
EPS
$0.08
+150.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
92.70M
+7.9% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AVXL (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer, Smaller reporting company
- SEC CIK
- 1314052
- Former names
- Thrifty Printing Inc. (until Jan 25, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | $6.7M | -$6.5M | -$6.8M | -$10.8M | -$14.5M |
| Net income | $7.8M | -$5.3M | -$5.7M | -$9.8M | -$13.2M |
| Diluted EPS | $0.08 | -$0.06 | -$0.06 | $0.00 | -$0.16 |
| Operating cash flow | -$9.1M | -$4.4M | -$7.2M | -$8.6M | -$12.5M |
| Total assets | $120.1M | $128.8M | $133.0M | $103.8M | $102.4M |
| Total liabilities | $7.7M | $7.1M | $6.4M | $8.9M | $11.5M |
| Stockholders' equity | $112.4M | $121.7M | $126.6M | $94.9M | $91.0M |
| Cash and investments | $118.3M | $127.4M | $131.7M | $102.6M | $101.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 1, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Change in control, Shareholder vote results
|
Sep 28, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
All 634 Anavex Life Sciences Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.